Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of Windsor

$91,840.00

Softabs-designing sugar-free viscoelastic drug delivery capsules for hydrophobic cannabinoid, nutraceutical, and pharmacological delivery across mucosal membranes

FY 2023-24

Summary
Cannabinoids, especially cannabidiol show promise as medicinal agents and are often now proscribed for a variety of indications. One of the major challenges is the lack of a standard dose, and safe ways to ingest. Smoking dried plant material causes harmful particles to enter the lungs, while homemade "edibles" can both vary in their potency and as they must pass through the liver due to digestion, can lead to different levels of cannabidiol entering the blood of different people. Oil tinctures are adsorbed across the mucosal membranes in the mouth, but are foul. In this three-year partnership, supported by NSERC and Mitacs, SofTab Technologies is partnering with University of Windsor Chemistry and Biochemistry professors Dr. John Trant and Dr. Simon Rondeau-Gagné to prepare a soft chewable formulation. These proposed SofTabs, although superficially similar to "gummies" are very different in practice. They are soft capsules of an emulsion of oils that dissolves in the mouth upon chewing and crosses the mucosal membranes moving directly into the blood stream. They are far more palatable than oils, and provide this defined dose in a simple form. The partners will work on designing new specific formulations for the vegan and halal markets as well as refining the formulation for different dosage forms and different levels of cannabis in the dose. This is challenging as any change to the formulation changes both the properties of the nanoemulsion AND the properties of the SofTab as a whole. To accelerate the work in the future, we hope to develop a better understanding and ability to predict precisely how changes in the ingredients affect these properties. This is generally useful to the scientific community as it provides insight into the self-assembly of complex amphiphilic systems. We will also look at how well the nanoemulsions cross the mucosal membrane using a mouse model to confirm how much of the dose is available to patients. The end-goal of this project is to produce a reliable, safe, and pleasant method for introducing medical cannabinoids, and it will be used to then expand this technology to other classes of vitamins and supplements that would benefit from the same approach.
Program
Alliance Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
571220-2021
Name nom
Trant, John JF
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2021
Award amount
91840
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Biomaterials
Research subject en
Science et technologie des matériaux
Research subject fr
Biomatériaux
Application title
Softabs-designing sugar-free viscoelastic drug delivery capsules for hydrophobic cannabinoid, nutraceutical, and pharmacological delivery across mucosal membranes
Keyword
analytical chemistry; bioavailability; cannabinoids; commercialization; emulsion; formulation science; nutrient additives; softab; surfactant; water-in-oil
Application summary
Cannabinoids, especially cannabidiol show promise as medicinal agents and are often now proscribed for a variety of indications. One of the major challenges is the lack of a standard dose, and safe ways to ingest. Smoking dried plant material causes harmful particles to enter the lungs, while homemade "edibles" can both vary in their potency and as they must pass through the liver due to digestion, can lead to different levels of cannabidiol entering the blood of different people. Oil tinctures are adsorbed across the mucosal membranes in the mouth, but are foul. In this three-year partnership, supported by NSERC and Mitacs, SofTab Technologies is partnering with University of Windsor Chemistry and Biochemistry professors Dr. John Trant and Dr. Simon Rondeau-Gagné to prepare a soft chewable formulation. These proposed SofTabs, although superficially similar to "gummies" are very different in practice. They are soft capsules of an emulsion of oils that dissolves in the mouth upon chewing and crosses the mucosal membranes moving directly into the blood stream. They are far more palatable than oils, and provide this defined dose in a simple form. The partners will work on designing new specific formulations for the vegan and halal markets as well as refining the formulation for different dosage forms and different levels of cannabis in the dose. This is challenging as any change to the formulation changes both the properties of the nanoemulsion AND the properties of the SofTab as a whole. To accelerate the work in the future, we hope to develop a better understanding and ability to predict precisely how changes in the ingredients affect these properties. This is generally useful to the scientific community as it provides insight into the self-assembly of complex amphiphilic systems. We will also look at how well the nanoemulsions cross the mucosal membrane using a mouse model to confirm how much of the dose is available to patients. The end-goal of this project is to produce a reliable, safe, and pleasant method for introducing medical cannabinoids, and it will be used to then expand this technology to other classes of vitamins and supplements that would benefit from the same approach.